ClinicalTrials.gg
RecruitingNCT07120880CombiChronoSUpdated Aug 12, 2026

Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia

A Phase 3 interventional study of AD + SHR + active LT and extended-release melatonin 2mg and AD + SHR + active LT and placebo melatonin in Major Depressive Disorder (MDD) With Insomnia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.

Planned enrollment
57th of 106
184 · median 232
Started
2026
with 6 others
Phase 3
36 of 127
2 open now
Primary completion
2028-08
later than 23 of 30 live
Registered
120th of 127
by date
Lead sponsor
7 of 127
Assistance Publique - Hôpitaux de Paris

Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 57th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2026, is one of 36 in phase 3, reaches primary completion later than 23 of the 30 other live ones, and was the 120th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Depressive Disorder, Major with a site in France, or all of them as a file.
02

Study summary

Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8 weeks of treatment. Insomnia, present in approximately 85% of individuals with MDD, is a frequent and persistent symptom that contributes to poor treatment outcomes. Targeting insomnia has been shown to enhance both symptom remission and functional recovery. In this context, combined therapeutic strategies are often used to optimize the antidepressant response. Among them, chronotherapeutic approaches, such as light therapy and prolonged-release melatonin, have demonstrated rapid antidepressant effects and are beneficial in regulating sleep and circadian rhythms. Light therapy shows an efficacy comparable to antidepressants and, when used in combination with them, can double treatment effectiveness. Melatonin is also recommended in the management of depression-related insomnia. This multicenter, randomized, double-blind, placebo-controlled trial with a 2x2 factorial design aims to evaluate the efficacy of two chronotherapeutic interventions, 8 weeks of active light therapy and 2 mg of prolonged-release melatonin-administered alone or in combination, on depressive symptom reduction at 8 weeks in adult patients with MDD and comorbid insomnia. The primary outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 8. All participants will receive antidepressant treatment and sleep hygiene education. This study proposes a novel therapeutic strategy combining pharmacological and non-pharmacological interventions to address both depression and insomnia, with the goal of improving outcomes, especially for the 40% of patients who do not adequately respond to antidepressants alone.

Read the detailed description

Major Depressive Disorder (MDD) affects approximately 5% of the global population and represents the second leading cause of disability worldwide. Despite the availability of pharmacological treatments, particularly antidepressants, their efficacy remains limited: nearly 50 to 60% of patients do not respond adequately after 8 weeks of treatment. One of the most common and persistent symptoms in MDD is insomnia, which affects about 85% of patients and frequently persists even after partial improvement of mood symptoms. Insomnia is not only a residual symptom but also a marker of poor prognosis and treatment resistance. Addressing sleep disturbances directly has been shown to enhance both symptomatic and functional remission in depression, making it a promising target for intervention.

In clinical practice, combination strategies are increasingly employed to improve therapeutic response, particularly in patients who are only partially responsive to antidepressant medication. Among these strategies, chronotherapeutic interventions, such as light therapy and prolonged-release melatonin, offer a compelling approach. These treatments have demonstrated rapid antidepressant effects, with some studies reporting clinical improvements as early as the first week of treatment. Additionally, both interventions are known to positively influence sleep quality and circadian rhythm regulation, which are often disrupted in depressive disorders.

Light therapy (LT), in particular, has shown efficacy comparable to that of antidepressants and works by synchronizing the sleep-wake cycle. When used in combination with antidepressants, LT has been associated with significantly greater reductions in depressive symptoms than antidepressants alone. Similarly, prolonged-release melatonin has been recommended in the management of insomnia comorbid with depression, further supporting the rationale for combining these chronotherapeutic agents.

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed in a 2x2 factorial format. It aims to evaluate the efficacy of two chronotherapeutic interventions, active light therapy (10,000 lux) for 8 weeks and 2 mg prolonged-release melatonin for 8 weeks, administered alone or in combination, in improving depressive symptoms at 8 weeks. The trial will enroll adult patients diagnosed with moderate to severe MDD and comorbid insomnia. The primary objective is to assess the change in depressive symptom severity, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) score, from baseline to week 8.

All participants, regardless of group allocation, will receive standard antidepressant treatment and structured sleep hygiene counseling to ensure a consistent baseline of care. This approach reflects real-world practices and enhances the ecological validity of the trial. The study also incorporates objective and subjective measures of sleep and circadian rhythms to explore the broader impact of the interventions.

By evaluating the combined and individual effects of light therapy and melatonin alongside standard care, this study seeks to establish an innovative and comprehensive therapeutic model. The goal is to improve outcomes for individuals with MDD and insomnia, particularly the substantial proportion of patients, up to 40%, who do not achieve adequate response with antidepressants alone. This trial represents a significant step toward more personalized, effective, and integrated treatment strategies for depression.

03

Conditions studied

  • Major Depressive Disorder (MDD) With Insomnia

Keywords

  • Major depressive episode
  • Insomnia
  • Light therapy
  • Melatonin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged between 18 and 65 years (to avoid the risk of cataract associated with light therapy) with a diagnosis of a major depressive episode (MDE) in the context of unipolar depression (according to criteria).
  2. Diagnosis of comorbid insomnia with the MDE, defined by difficulty initiating sleep, and/or maintaining sleep, and/or early morning awakenings with daytime consequences, occurring at least three times per week (according to DSM-5 and ICSD-3, in line with European guideline recommendations).
  3. Outpatients or inpatients treated for MDE in one of the psychiatric departments of the study centers, or in the sleep medicine department, for a minimum treatment duration of 8 weeks.
  4. Patients not currently receiving antidepressant treatment for the current MDE (previous use of antidepressants is allowed, provided treatment was stopped at least one month prior to study participation).
  5. A MADRS score ≥ 20 (clinician-rated), indicating at least a moderate-intensity depressive episode.
  6. An ISI score ≥ 8 (clinician-rated), indicating at least mild and insomnia.
  7. No exposure to light therapy in the month prior to inclusion.
  8. Ability to understand and sign the form.
  9. Use of highly effective for women of .

Exclusion criteria

Exclusion Criteria:

  1. Individuals under legal guardianship or deprived of liberty
  2. Ophthalmologic conditions (e.g., cataract, glaucoma, age-related macular degeneration) or diseases affecting the retina (e.g., retinitis pigmentosa, diabetes, herpes, etc.)
  3. The following disorders (according to ): schizophrenia and other psychotic disorders; bipolar disorder, particularly (hypo)manic episodes (YMRS score ≥ 12); other unstable mental disorders
  4. Other unstable general medical conditions
  5. Pregnant or breastfeeding women
  6. Hypersomnia with prolonged total sleep time secondary to the depressive episode, according to ICSD-3 criteria
  7. Current depressive episode already being treated with an antidepressant
  8. Presence of a high suicidal risk, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, score ≥ 4)
  9. Ongoing melatonin treatment at the time of inclusion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
184 participants (estimated)

Study arms

  • Active comparator
    A

    Patients receiving active light therapy (approx. 10,000 Lux) and prolonged-release melatonin 2 mg taken 1 hour before bedtime, in combination with sleep and hygiene rules (SHR) and antidepressant treatment (AD)

    Procedure: AD + SHR + active LT and extended-release melatonin 2mg

  • Active comparator
    B

    Patients receiving active light therapy (approx. 10,000 Lux) and placebo melatonin, in combination with SHR and AD.

    Procedure: AD + SHR + active LT and placebo melatonin

  • Active comparator
    C

    Patients receiving placebo light therapy (filtered to approx. \<10 Lux) and prolonged-release melatonin 2 mg taken 1 hour before bedtime, in combination with SHR and AD.

    Procedure: AD + SHR + placebo LT and extended-release melatonin 2mg

  • Placebo comparator
    D

    Patients receiving placebo light therapy (filtered to approx. \<10 Lux) and placebo melatonin (control group), in combination with SHR and AD.

    Procedure: AD + SHR + placebo LT and placebo melatonin

Interventions

  • ProcedureAD + SHR + active LT and extended-release melatonin 2mg

    Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.

  • ProcedureAD + SHR + active LT and placebo melatonin

    Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.

  • ProcedureAD + SHR + placebo LT and extended-release melatonin 2mg

    Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.

  • ProcedureAD + SHR + placebo LT and placebo melatonin

    Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.

06

What researchers measure

Primary outcomes

  1. Assessment of the efficacy of two chronotherapeutics (LT and extended-release melatonin 2mg), alone or combined, associated to AD on depressive symptoms reduction after 8 weeks of treatment

    Measure the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score between the inclusion visit (V0, S0) and Week 8 (V3, S8) in patients with moderate to severe major depressive episode and insomnia

    Time frame: At baseline (Week 0) and at Week 8

Secondary outcomes

  1. Assessment of the efficacy of chronotherapeutics, combine or alone, on depressive symptoms evolution

    Measure changes in MADRS scores from baseline (inclusion visit) to each follow-up visit (Week 1, Week 4, Week 8, and Month 3).

    Time frame: Weeks 1, 4, 8, and Month 3

  2. Determination of the rate of therapeutic response to chronotherapeutics at each follow-up visit

    Proportion of patients achieving ≥50% reduction in MADRS score at each follow-up visit (Week 1, Week 4, Week 8 and Month 3) as compared to baseline (inclusion visit)

    Time frame: Weeks 1, 4, 8, and Month 3

  3. Determination of the rate of remission in depressive symptoms

    Proportion of patients with MADRS score ≤10 at specified time points (Weeks 4, 8 and Month 3).

    Time frame: Weeks 4, 8, and Month 3

  4. Evaluation of the impact of chronotherapeutics on subjective sleep

    Assessment using self-reported sleep questionnaires, sleep-wake rhythm diaries, and sleep logs

    Time frame: Weeks 1, 4, 8, and Month 3

  5. Evaluation of the impact of chronotherapeutics on circadian rhythm

    Assessment using self-reported sleep questionnaires, sleep-wake rhythm diaries, and sleep logs

    Time frame: Weeks 1, 4, 8, and Month 3

  6. Evaluation of changes in objective sleep measured by actigraphy

    Total sleep time

    Time frame: Weeks 1, 4, and 8

  7. Evaluation of changes in objective sleep measured by actigraphy

    Wake After Sleep Onset (WASO)

    Time frame: Weeks 1, 4, and 8

  8. Evaluation of changes in objective sleep measured by actigraphy

    Fragmentation index

    Time frame: Weeks 1, 4, and 8

  9. Evaluation of changes in objective sleep measured by actigraphy

    Sleep efficiency

    Time frame: Weeks 1, 4, and 8

  10. Evaluation of changes in objective sleep measured by actigraphy

    Time in bed

    Time frame: Weeks 1, 4, and 8

  11. Evaluation of changes in sleep rhythm parameters measured by actigraphy

    Total Sleep Time

    Time frame: Weeks 1, 4, and 8

  12. Evaluation of changes in sleep rhythm parameters measured by actigraphy

    Wake After Sleep Onset (WASO)

    Time frame: Weeks 1, 4, and 8

  13. Evaluation of changes in sleep rhythm parameters measured by actigraphy

    Fragmentation Index

    Time frame: Weeks 1, 4, and 8

  14. Evaluation of changes in sleep rhythm parameters measured by actigraphy

    Sleep Efficiency

    Time frame: Weeks 1, 4, and 8

  15. Evaluation of changes in sleep rhythm parameters measured by actigraphy

    Time in Bed

    Time frame: Weeks 1, 4, and 8

  16. Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters

    Relative amplitude

    Time frame: Weeks 1, 4, and 8

  17. Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters

    Interdaily stability/variability

    Time frame: Weeks 1, 4, and 8

  18. Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters

    L5/M10 onset markers

    Time frame: Weeks 1, 4, and 8

  19. Modeling of the longitudinal trajectory of MADRS scores

    Analyze the slope of MADRS score changes across visits to characterize symptom progression or improvement.

    Time frame: From baseline to Week 8 and from baseline to Month 3

  20. Measurement of time to therapeutic response

    Time (in days) from inclusion to achievement of ≥50% reduction in MADRS score.

    Time frame: From baseline to Month 3

  21. Evaluation of the tolerability of chronotherapeutic combinations

    Evaluate adverse events using the PRISE-M side effects questionnaire.

    Time frame: Weeks 1, 4, and 8

  22. Evaluation of mood state

    Scores on YMRS (mania)

    Time frame: Weeks 1, 4, 8, and Month 3

  23. Evaluation of mood state

    C-SSRS (suicidal ideation)

    Time frame: Weeks 1, 4, 8, and Month 3

  24. Evaluation of mood state

    QIDS-SR (depression)

    Time frame: Weeks 1, 4, 8, and Month 3

  25. Evaluation of mood state

    GAD-7 (anxiety)

    Time frame: Weeks 1, 4, 8, and Month 3

  26. Evaluation of mood state

    CGI (clinical global impression)

    Time frame: Weeks 1, 4, 8, and Month 3

  27. Evaluation of global functioning evolution

    Scores on YMRS (mania)

    Time frame: Weeks 1, 4, 8, and Month 3

  28. Evaluation of global functioning evolution

    C-SSRS (suicidal ideation)

    Time frame: Weeks 1, 4, 8, and Month 3

  29. Evaluation of global functioning evolution

    QIDS-SR (depression)

    Time frame: Weeks 1, 4, 8, and Month 3

  30. Evaluation of global functioning evolution

    GAD-7 (anxiety)

    Time frame: Weeks 1, 4, 8, and Month 3

  31. Evaluation of global functioning evolution

    CGI (clinical global impression)

    Time frame: Weeks 1, 4, 8, and Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Aug 13, 2025
StartActual
Jan 28, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Jan 2029
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07120880
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Jan 28, 2026
Primary completion
Aug 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Aug 12, 2026

Study contacts

Pierre-Alexis GEOFFROY, Pr, med
Contact
pierrealexis.geoffroy@aphp.fr
+33 1 40 25 62 72
Julia MARUANI, Dr, med
Contact
julia.maruani@aphp.fr
+33 1 40 25 62 72
Pierre-Alexis GEOFFROY, Pr
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion